Leap Therapeutics Inc (LPTX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Leap Therapeutics Inc (LPTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9861
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Leap Therapeutics Inc (Leap Therapeutics), formerly HealthCare Pharmaceuticals Inc, is a clinical-stage biopharmaceutical company that develops novel therapeutics to treat patients with cancer. The company’s pipeline products include DKN-01, a humanized monoclonal antibody that targets the Dickkopf-1 (DKK-1) protein, intended for the treatment of gastroesophageal cancer, biliary tract cancer, hepatocellular carcinoma, and non-small cell lung cancer; and TRX518, is a humanized anti-GITR (glucocorticoid-induced tumor necrosis factor receptor) monoclonal antibody that enhances the immune system’s anti-tumor response and is in Phase 1 clinical trials intended for the treatment of solid tumors. Leap Therapeutics is headquartered in Cambridge, Massachusetts, the US.

Leap Therapeutics Inc (LPTX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Leap Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Leap Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
GITR Raises US$3.25 Million In Seed Financing 12
Partnerships 13
Leap Therapeutics Enters into Co-Development Agreement with Merck and Pfizer 13
Leap Therapeutics Enters into Immunotherapy Agreement with European Organisation for Research and Treatment of Cancer 14
Leap Therapeutics Enters into Agreement with Merck International 15
Merger 16
GITR Merges with HealthCare Pharmaceuticals to Form Leap Therapeutics 16
Licensing Agreements 17
Leap Therapeutics Enters into Licensing Agreement with Lonza Sales 17
Equity Offering 18
Leap Therapeutics Raises USD16.1 Million in Public Offering of Shares 18
Leap Therapeutics Plans to Raise Funds in Secondary Offering of Shares 20
Leap Therapeutics to Raise USD18 Million in Private Placement of Units 21
Macrocure Completes IPO for USD54 Million 23
Acquisition 25
Leap Therapeutics Acquires Macrocure 25
Leap Therapeutics Inc – Key Competitors 27
Leap Therapeutics Inc – Key Employees 28
Leap Therapeutics Inc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Aug 08, 2018: Leap Therapeutics reports second quarter 2018 business update and financial results 30
May 11, 2018: Leap Therapeutics Reports First Quarter 2018 Financial Results 32
Feb 23, 2018: Leap Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results 33
Nov 13, 2017: Leap Therapeutics Reports Third Quarter 2017 Financial Results 35
Aug 11, 2017: Leap Therapeutics Reports Second Quarter 2017 Financial Results 36
May 12, 2017: Leap Therapeutics Reports First Quarter 2017 Financial Results 37
May 12, 2017: Leap Therapeutics Q1 net loss increases 38
Mar 31, 2017: Leap Therapeutics Reports Full Year 2016 Financial Results and Progression-Free Survival Data in Advanced Biliary Tract Cancers 39
Product News 40
04/16/2018: Leap Therapeutics Presents Nonclinical and Clinical Data on DKN-01 at AACR 2018 Annual Meeting 40
03/01/2017: Leap Therapeutics to Present Clinical Data on TRX518 at 2017 AACR Annual Meeting 41
03/01/2017: Leap Therapeutics to Present Data on DKN-01 at 2017 AACR Annual Meeting 42
02/03/2017: Leap Therapeutics Presents Biomarker and Efficacy Data at the Cholangiocarcinoma Foundation 2017 Annual Meeting 43
01/19/2017: Leap Therapeutics Presents Biomarker Data from Clinical Study of DKN-01 in Combination with Paclitaxel in Esophageal Cancer 44
Clinical Trials 45
Mar 14, 2018: Leap Therapeutics Provides DKN-01 Program Update and Announces Scientific Presentations at AACR Annual Meeting 45
Jan 16, 2018: Leap Therapeutics Announces First Patient Dosed with TRX518 Combination Therapy in Advanced Solid Tumors Trial 47
Nov 13, 2017: Leap Therapeutics Announces First Patient Dosed with DKN-01 and KEYTRUDA (pembrolizumab) in Esophagogastric Cancer Trial 48
Nov 13, 2017: Leap Therapeutics Provides Update on its Antineoplastic Drug Candidate TRX-518 49
May 17, 2017: Leap Therapeutics Presents Positive DKN-01 Clinical Data in Biliary Tract Cancers at American Society of Clinical Oncology 2017 Annual Meeting 50
May 12, 2017: Leap Therapeutics Provides Update on DKN-01 51
Apr 20, 2017: Leap Therapeutics to Present DKN-01 Clinical Data at American Society of Clinical Oncology 2017 Annual Meeting 52
Apr 03, 2017: Leap Therapeutics Presents Data on DKN-01 at the 2017 AACR Annual Meeting 53
Apr 03, 2017: Leap Therapeutics Presents Non-clinical and Phase 1 Data for TRX518 at the 2017 AACR Annual Meeting 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55

List of Tables
Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Leap Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Leap Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Leap Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
GITR Raises US$3.25 Million In Seed Financing 12
Leap Therapeutics Enters into Co-Development Agreement with Merck and Pfizer 13
Leap Therapeutics Enters into Immunotherapy Agreement with European Organisation for Research and Treatment of Cancer 14
Leap Therapeutics Enters into Agreement with Merck International 15
GITR Merges with HealthCare Pharmaceuticals to Form Leap Therapeutics 16
Leap Therapeutics Enters into Licensing Agreement with Lonza Sales 17
Leap Therapeutics Raises USD16.1 Million in Public Offering of Shares 18
Leap Therapeutics Plans to Raise Funds in Secondary Offering of Shares 20
Leap Therapeutics to Raise USD18 Million in Private Placement of Units 21
Macrocure Completes IPO for USD54 Million 23
Leap Therapeutics Acquires Macrocure 25
Leap Therapeutics Inc, Key Competitors 27
Leap Therapeutics Inc, Key Employees 28
Leap Therapeutics Inc, Subsidiaries 29

List of Figures
Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Leap Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Leap Therapeutics Inc (LPTX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • IntriCon Corp (IIN):企業の財務・戦略的SWOT分析
    Summary IntriCon Corp (IntriCon) is a designer, developer and manufacturer of miniature and micro-miniature body-worn medical and electronics products. The company’s products comprise value hearing health, biomedical solutions, hearing health manufacturing and professional audio. In addition it also …
  • Synthetic Biologics Inc (SYN):企業の財務・戦略的SWOT分析
    Summary Synthetic Biologics Inc (Synthetic Biologics), formerly Adeona Pharmaceuticals Inc is a clinical company that develops novel therapeutics to treat gut microbiome. The company’s pipeline products include SYN-004 and SYN-010. Its SYN-010 is a proprietary, modified-release formulation which is …
  • The Menarini Group:企業のM&A・事業提携・投資動向
    The Menarini Group - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The Menarini Group Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • EnBW Energie Baden-Wurttemberg AG:発電所・企業SWOT分析
    EnBW Energie Baden-Wurttemberg AG - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on …
  • PlantForm Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary PlantForm Corp (PlantForm) is a biopharmaceutical company that develops and produces specialty antibody and protein drugs. The company’s pipeline products include biosimilar ranibizumab, trastuzumab, hD9 antibody for ricin exposure, recombinant butyrylcholinesterase, antibodies for HIV or AI …
  • Sygnature Discovery Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Sygnature Discovery Ltd (Sygnature) is a drug discovery company that offers medicinal chemistry, bioscience, computational chemistry, and fragment-based drug discovery programs. The company offers services for various phases of drug discovery which include hit identification, hit to lead, an …
  • GFI Informatique:企業の戦略・SWOT・財務分析
    GFI Informatique - Strategy, SWOT and Corporate Finance Report Summary GFI Informatique - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • BARMER GEK:企業の戦略的SWOT分析
    BARMER GEK - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • BORSIG ZM Compression GmbH:企業の戦略的SWOT分析
    BORSIG ZM Compression GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Becton Dickinson and Co (BDX):医療機器:M&Aディール及び事業提携情報
    Summary Becton Dickinson and Co (BD) is a medical technology company that manufactures and sells medical devices, reagents and instruments. Its major products include syringes and pen needles; intravenous catheters; infusion pumps and disposables; automated medication dispensing and supply managemen …
  • ONCOVEDA Cancer Research Center:企業の製品パイプライン分析
    Summary ONCOVEDA Cancer Research Center (Oncoveda), a part of Medical Diagnostic Laboratories LLC, is a cancer research center. The center provides research and development programs for cancer, early detection, monitoring, and treatment of bladder and endometrial cancers, and tumor progression and r …
  • Kura Oncology Inc (KURA):企業の財務・戦略的SWOT分析
    Summary Kura Oncology Inc (Kura Oncology) is a clinical-stage biopharmaceutical company that discovers and develops therapeutics for the treatment of solid tumors and blood cancers. The company’s lead drug candidate Tipifarnib, an inhibitor of farnesyl transferase, an oral investigational drug candi …
  • Sophiris Bio Inc (SPHS):製薬・医療:M&Aディール及び事業提携情報
    Summary Sophiris Bio Inc (Sophiris) is a clinical stage bio-pharmaceutical company, which focuses on developing products for the treatment of urological diseases. Sophiris lead drug candidate, PRX302 is under late stage development for the treatment of lower urinary tract symptoms of benign prostati …
  • SciBase AB (SCIB):企業の財務・戦略的SWOT分析
    Summary SciBase AB (SciBase) is a medical technology company that offers non-invasive detection and monitoring of skin tissue alterations. The company develops point of care device for the accurate detection of malignant melanoma. It offers electrical impedance spectroscopy which uses the varying el …
  • HeartSine Technologies LLC:企業の戦略的SWOT分析
    HeartSine Technologies LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Marmen Inc:企業の戦略的SWOT分析
    Marmen Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Republic Services Inc (RSG):企業の財務・戦略的SWOT分析
    Republic Services Inc (RSG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Formosa Plastics Corp (1301):企業の財務・戦略的SWOT分析
    Formosa Plastics Corp (1301) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Pilgrim’s Pride Corp (PPC):企業の財務・戦略的SWOT分析
    Pilgrim's Pride Corp (PPC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Juvenile Diabetes Research Foundation-製薬・医療分野:企業M&A・提携分析
    Summary Juvenile Diabetes Research Foundation (JDRF) is a research organization that offers funding services for type one diabetes. The organization conducts clinical trials for curing, preventing and treating for type one diabetes and its complications; and researching new drugs for patients to man …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆